betahistine | Betaserc tablets 16 mg, 30 pcs.

Latin name

Betaserc

Release form

Tablets.

Packing

30 pcs

Pharmacological action

Betaserc - improves microcirculation.

Pharmacodynamics

Betaserc (betahistine) acts primarily on the histamine H1 and H3 receptors of the inner ear and vestibular nuclei of the central nervous system. By direct agonistic action on the H1 receptors of the vessels of the inner ear, and also indirectly through exposure to H3 receptors it improves microcirculation and capillary permeability, normalizes endolymph pressure in the labyrinth and cochlea. However, betahistine increases blood flow in the basilar arteries. Betaserk® also has a pronounced central effect due to the influence of the vestibular nerve nuclei on the H3 receptors. Normalizes the conductivity in neurons of the vestibular nuclei at the level of the brain stem. A clinical manifestation of these properties is a decrease in the frequency and intensity of dizziness, a decrease in tinnitus, and an improvement in hearing if it is reduced.

Indications

vestibular dizziness

syndromes characterized by dizziness and headache, tinnitus, progressive hearing loss, nausea and vomiting

disease / Meniere's syndrome.

Contraindications

hypersensitivity to any of the components of the drug

pheochromocytoma

peptic ulcer of the stomach and duodenum in the acute phase.

Use during pregnancy and lactation

There is insufficient data on the use of betahistine in pregnant women. The potential risk to humans is unknown. Betagistin should not be used during pregnancy unless absolutely necessary.

It is not known whether betahistine and breast milk are excreted. You should not prescribe the drug during breastfeeding. The question of the appointment of BetaserkВ® mother should be taken only after comparing the benefits of breastfeeding with the potential risk to the infant.

Composition

1 tablet contains:

Active ingredient: betahistine dihydrochloride - 16 mg.

Excipients: microcrystalline cellulose - 161.5 mg, mannitol (E421) - 50 mg, citric acid monohydrate - 5 mg, colloidal silicon dioxide - 5 mg, talc - 12.5 mg.

Dosage and administration of

The drug is administered orally with food. The dose should be selected individually depending on the response to treatment.

For adults, the dose is 24-48 mg / day.

Dose / frequency of administration:

Betaserc® 8 mg - 1-2 tablets 3 times a day.

Betaserc® 16 mg - 1 / 2-1 tablets 3 times a day.

Betaserc® 24 mg - 1 tablet 2 times a day.

16 mg tablet and 24 mg tablet can be divided into 2 equal parts. To do this, place the tablet on a hard surface with the scuff up and press on it with your thumb.

Improvement is sometimes observed only after a few weeks of treatment, and a stable therapeutic effect after several months of treatment. There is evidence that the appointment of the drug at the beginning of the disease prevents its progression and / or hearing loss in later stages.

Despite the limited clinical trial data, extensive post-registration experience suggests that dose adjustment in elderly patients is not required.

No specific clinical studies have been conducted in patients with renal and / or liver failure, however post-registration experience suggests that dose adjustment in this group of patients is not required.

Side effects

Gastrointestinal upsets (nausea, feeling of heaviness in the epigastrium) are possible, which can be prevented by taking the drug after meals or by reducing the dose. In very rare cases, the appearance of hypersensitivity reactions from the skin, in particular, skin rash, itching, and urticaria.

Overdose

Symptoms: mild and moderate nausea, drowsiness, and abdominal pain were observed in some patients after up to 640 mg. More serious complications (convulsions, cardiopulmonary complications) were observed with the intentional administration of betahistine in high doses, especially in combination with an overdose of other drugs.

Treatment: carrying out symptomatic therapy.

Storage conditions

The drug should be stored out of the reach of children, in a dry place at a temperature not exceeding 25 РC.

Expiration

5 years.

Deystvuyuschee substances

betahistine

dosage form

drug venal form

tablets